Restore Hyper Wellness
1040 South Fowler Avenue, Unit 205 · Bozeman, MT 59718
5.0(628 Google reviews · 96 in past year)
Retatrutide isn't available here yet. These are practices that treat weight and metabolic health, and some prescribe FDA-approved GLP-1s today. Inclusion does not mean a provider offers retatrutide.
1040 South Fowler Avenue, Unit 205 · Bozeman, MT 59718
5.0(628 Google reviews · 96 in past year)
1188 North 15th Avenue · Bozeman, MT 59715
4.9(187 Google reviews · 27 in past year)
5140 Avenida Encinas · Bozeman, MT 59715
4.9(160 Google reviews · 37 in past year)
1958 Stadium Drive · Bozeman, MT 59715
4.8(147 Google reviews · 9 in past year)
132 North Higgins Avenue · Bozeman, MT 59718
5.0(119 Google reviews · 25 in past year)
1195 Stoneridge Drive · Bozeman, MT 59718
5.0(48 Google reviews · 39 in past year)
804 North 19th Avenue · Bozeman, MT 59718
4.6(36 Google reviews)
985 Technology Boulevard · Bozeman, MT 59718
5.0(13 Google reviews · 1 in past year)
Pins reflect street addresses where available; others are approximate (ZIP-level).
Be first to know when its status changes — join thousands already on the list.
No. Retatrutide is investigational and not FDA-approved, so it is not available by prescription in Bozeman or anywhere else in the U.S. The only legitimate routes today are clinical trials and Lilly's expanded access program, where your physician applies on your behalf and medical criteria must be met. RetaMaps tracks the status and the local providers most relevant to future treatment.
They are practices in medical weight management, obesity medicine, endocrinology, metabolic health, and related fields. Some currently advertise FDA-approved GLP-1 medications such as semaglutide or tirzepatide; each profile shows what the practice publicly advertises today.
Yes — 1 of the 13 tracked providers in this market indicate telehealth visits. State licensing rules determine whether a given telehealth practice can serve Montana residents; confirm with the practice.
No. Inclusion on RetaMaps does not mean a provider offers or will offer retatrutide — and no legitimate provider can prescribe it today. Where a practice has told RetaMaps directly that it expects to offer retatrutide if approved, we mark that clearly on its profile.
Join the RetaMaps update list with your email and ZIP. We'll email when retatrutide's regulatory or commercial status changes relevant to your area. It's informational — not a treatment queue.